Bionow Investment Showcase Webinar - AMLo Biosciences & CrystecPharma
Online event
Wednesday 26th March
About
Bionow's Investment Showcase Webinar series continues and we are really pleased to invite two ambitious life science companies to take part in the next webinar. Both businesses are innovative and revenue generating, this is a unique opportunity to pitch to a targeted audience of investors actively seeking high-growth opportunities.
AMLo is a female founded, female led diagnostic company developing innovative products for skin cancer indications. Their first product for early-stage melanoma is on the market in UK and US and their pipeline of related AI enabled products are in late validation ready for launch in 2026. They are raising a Series A round of £10m to advance their product development pipeline, set up a UK based CLIA lab to service the US market directly, and expand their sales and marketing efforts in their key markets. This is an exciting opportunity to invest in a company with derisked technology, evidence of early adoption in two key markets, with an anticipated exit by acquisition in the next 24 months.
Crystec is a crystal and particle engineering company applying its proprietary and award-winning mSAS® (modified Supercritical Anti-Solvent) technology to enable small and large molecules to be manufactured in ways that greatly enhance their therapeutic performance, thereby transforming the quality of life for many patients. Crystec applies its technology to develop innovative therapeutics in areas of high unmet need.
Each company will have 30 minutes to pitch, sharing compelling data and their investment proposition. If you’re interested in securing a slot, get in touch today!
Please email david.holmes@bionow.co.uk if you are intrested in presenting.
AMLo is a female founded, female led diagnostic company developing innovative products for skin cancer indications. Their first product for early-stage melanoma is on the market in UK and US and their pipeline of related AI enabled products are in late validation ready for launch in 2026. They are raising a Series A round of £10m to advance their product development pipeline, set up a UK based CLIA lab to service the US market directly, and expand their sales and marketing efforts in their key markets. This is an exciting opportunity to invest in a company with derisked technology, evidence of early adoption in two key markets, with an anticipated exit by acquisition in the next 24 months.
Crystec is a crystal and particle engineering company applying its proprietary and award-winning mSAS® (modified Supercritical Anti-Solvent) technology to enable small and large molecules to be manufactured in ways that greatly enhance their therapeutic performance, thereby transforming the quality of life for many patients. Crystec applies its technology to develop innovative therapeutics in areas of high unmet need.
Each company will have 30 minutes to pitch, sharing compelling data and their investment proposition. If you’re interested in securing a slot, get in touch today!
Please email david.holmes@bionow.co.uk if you are intrested in presenting.
Key Information
Where: Online Event
When: Wednesday 26th March
From 2pm!
Registration
Registration will open shortly. For any further queries please contact info@bionow.co.uk